Key Highlights
- YUTREPIA net product sales rose 31% sequentially to USD 222.7 million, lifting total Revenue to USD 225.3 million.
- A one-time USD 389.7 million settlement charge drove a GAAP net loss of USD 236.3 million, or 2.64 per share.
- Adjusted EBITDA reached USD 140.5 million, the fifth consecutive quarterly increase, with gross Margin near 94%.
- Cash ended at USD 396.1 million before settlement payments, with USD 380.7 million of the charge payable through April 2027.
Liquidia (NASDAQ:LQDA) reported third quarter 2026 revenue of USD 225.3 million, above the USD 214.2 million estimate, but a one-time settlement charge pushed GAAP results to a net loss of USD 236.3 million, or USD 2.64 per share, against an estimated profit of USD 0.96. Net product sales of its inhaled treprostinil product YUTREPIA were USD 222.7 million, up USD 52 million, or 31%, from the second quarter, of which USD 212.2 million was paid patient demand.
Management said YUTREPIA has now delivered five consecutive quarters of growth in prescriptions, revenue and adjusted EBITDA. More than 60% of prescriptions since launch have included a pulmonary arterial hypertension diagnosis, rising above 70% in September. About 60% of prescribers have written for two or more patients and more than 30% for at least five.
Settlement Drives the GAAP Loss
The loss reflects a one-time charge of USD 389.7 million tied to the resolution of litigation with United Therapeutics and related agreements, of which USD 380.7 million is payable in cash through April 2027. The quarterly filing describes the payments made in October: an initial USD 185.0 million payment to United Therapeutics, a USD 10.0 million payment received from that company, USD 21.75 million placed In Escrow for Sandoz, USD 19.05 million paid to a litigation financing counterparty, and USD 19.45 million paid under a separate agreement with a pharmacy benefit manager. Standby letters of Credit totaling USD 145.4 million were issued to secure the remaining payments.
The Sandoz promotion agreement was terminated in October, so service revenue from it ends. Excluding the settlement charge, operating trends were strong: cost of product sales rose in line with sales, leaving gross margin near 94%. Research and Development expense rose 47% sequentially to USD 25.3 million as enrollment ramped in a pivotal study, while selling, general and administrative expense fell to 26% of revenue from 33%. Adjusted EBITDA reached USD 140.5 million.
Pipeline and Demand Indicators
Management said the daily referral rate in October was above 75% of the third quarter daily rate, with conversion rates above 87% and no change in formulary status. It estimates that about 80% of roughly USD 4.9 billion in annual US branded prostacyclin sales goes to patients with pulmonary arterial hypertension.
Development plans include RE-WARM, a dose-finding study in systemic sclerosis with Raynaud's phenomenon, with completion projected in the first half of 2027, and RE-SPIRE, a pivotal study in pulmonary hypertension with interstitial lung disease, with enrollment completing in 2028 and data supporting a submission in 2029. A registry study called EASY-PAH is planned for 2027, and a pivotal PH-COPD study is planned for the second half of next year.
Asked about 2027, management said it wants more data before providing guidance and would share expectations around early January. Management also described an earlier settlement offer from its competitor as economically unattractive.
Litigation and Demand Markers to Watch
The company's filing refers readers to its legal proceedings note and warns that volatile share prices can draw securities class action litigation. The key items going forward are the schedule of settlement cash payments through April 2027, referral and conversion trends after the transition period management described, and progress of the registry and pivotal studies.
_11_19_2026_19_19_13_574021.jpg)





Please wait processing your request...